Kidney transplantation remains the gold standard treatment for eligible patients with end-stage renal disease, providing substantial survival benefits and enhanced quality of life compared to maintenance dialysis. However, long-term post-transplant survival is heavily influenced by preexisting comorbidities, particularly diabetes mellitus. A landmark European Renal Association (ERA) Registry study evaluating adult recipients has shed vital light on kidney transplant mortality patterns spanning nearly two decades. By analyzing data from 134,231 adult recipients who underwent a first kidney transplantation across twelve European countries between 2005 and 2022, researchers explored both all-cause and cause-specific mortality trajectories. The findings underscore critical clinical challenges, highlighting persistent survival gaps that modern cardiorenal and immunosuppressive therapies have yet to overcome.

Understanding the Overall Kidney Transplant Mortality Disparities

Among the large cohort analyzed, 20,753 recipients (15.5%) presented with diabetes mellitus as the primary cause of kidney failure. The study demonstrated that adult recipients with diabetic kidney disease faced almost double the mortality rate of recipients without diabetes. Specifically, the age- and sex-standardized mortality rate reached 45.5 deaths per 1,000 person-years in recipients with diabetes, compared to 24.9 deaths per 1,000 person-years among those without diabetes. Consequently, this considerable difference emphasizes the high baseline vulnerability of diabetic transplant recipients. While overall survival after kidney transplantation remains far superior to remaining on maintenance dialysis, these registry data indicate that preexisting vascular and systemic metabolic insults significantly shorten post-transplant life expectancy. Therefore, clinicians must recognize that restoration of renal filtration through transplantation does not completely eliminate the cumulative cardiorenal damage sustained during years of poorly controlled glycemic and uremic exposure.

Cardiovascular Disease Drivers in Post-Transplant Outcomes

Cardiovascular disease represents the leading contributor to the widened survival gap between diabetic and non-diabetic graft recipients. The excess mortality observed among recipients with diabetes in the ERA Registry cohort was primarily attributable to atherosclerotic cardiovascular complications, heart failure, and sudden cardiac death. In the general non-transplant population, advances in preventive cardiology, including aggressive lipid-lowering therapy, potent antihypertensive regimens, and revascularization procedures, have markedly reduced cardiovascular mortality rates over the past two decades. However, the study revealed that cardiovascular mortality rates among kidney transplant recipients remained entirely flat between 2005 and 2022. Moreover, the absolute cardiovascular mortality gap between diabetic and non-diabetic recipients failed to narrow over time. This stagnation suggests that traditional cardiovascular risk reduction strategies may be attenuated by post-transplant factors, including calcineurin inhibitor-induced hypertension, new-onset dyslipidemia, corticosteroid therapy, and vascular calcification.

Infection-Related Mortality and the Pandemic Impact

In addition to cardiovascular events, infectious complications constituted the second major driver of excess mortality among diabetic kidney transplant recipients. Long-term maintenance immunosuppression impairs both cellular and humoral immunity, rendering transplant recipients uniquely susceptible to bacterial, viral, and opportunistic fungal pathogens. Patients with diabetes suffer from baseline leukocyte dysfunction, microvascular ischemia, and impaired epithelial barriers, compounding their vulnerability to severe infections. The ERA Registry data showed that infection-related mortality remained stable until the onset of the COVID-19 pandemic. During the pandemic years, however, both diabetic and non-diabetic cohorts experienced sharp surges in all-cause mortality, overwhelmingly driven by severe respiratory infections. Because diabetic patients mounted poorer vaccine responses and had higher rates of severe viral pneumonia, the pandemic period intensified absolute mortality disparities across European renal transplant programs.

Long-Term Stability of Secular Mortality Trends

A central finding of the ERA Registry investigation is the remarkable stability of age- and sex-standardized all-cause mortality rates over the 17-year observational timeframe prior to 2020. Using Joinpoint regression analysis, investigators observed no significant downward trend in all-cause mortality for either diabetic or non-diabetic first kidney transplant recipients. This lack of secular improvement stands in stark contrast to broader epidemiologic trends observed across Western populations, where life expectancy and cardiovascular survival have progressively improved. Several factors likely explain this plateau within the transplant population. Over recent decades, transplant acceptance criteria have broadened substantially, resulting in older, more complex recipients receiving grafts from expanded-criteria donors. Although surgical techniques and acute rejection management have steadily advanced, these donor and recipient risk profiles likely counterbalance improvements in short-term graft preservation.

Clinical Strategies to Mitigate Cardiorenal Risks in Practice

Addressing the persistent mortality gap requires a comprehensive, proactive paradigm shift in post-transplant clinical management. First, clinicians should implement rigorous cardiovascular surveillance protocols before and after transplantation, utilizing functional testing and coronary imaging when indicated. Second, multidisciplinary care teams should prioritize contemporary cardioprotective pharmacotherapy. Emerging agents, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists, have proven cardiovascular and renal benefits in native chronic kidney disease; their safe, expanded implementation in stable transplant cohorts warrants active adoption. Furthermore, optimizing immunosuppressive regimens to minimize metabolic toxicity—such as rapid steroid withdrawal or calcineurin inhibitor minimization—can attenuate post-transplant dysglycemia. Finally, aggressive infection prophylaxis, robust vaccination schedules, and prompt antimicrobial intervention are vital to protecting these high-risk patients from lethal infectious complications.

Frequently Asked Questions

Why is mortality higher in diabetic kidney transplant recipients?

Diabetic kidney transplant recipients experience higher mortality primarily due to accelerated cardiovascular disease and heightened susceptibility to severe infections. Years of chronic hyperglycemia, vascular calcification, and systemic inflammation create extensive arterial and myocardial damage prior to transplantation. Furthermore, post-transplant immunosuppression combined with diabetic leukocyte dysfunction impairs protective immune responses, substantially raising the likelihood of fatal sepsis and severe systemic infections.

Did cardiovascular mortality improve among transplant recipients over time?

Contrary to positive trends observed in the general population, cardiovascular mortality rates among kidney transplant recipients did not improve significantly between 2005 and 2022. The ERA Registry data revealed that the cardiovascular mortality gap between diabetic and non-diabetic recipients remained stable over time, highlighting that current clinical management protocols have not yet overcome the persistent cardiovascular risks inherent to organ transplantation and long-term immunosuppression.

How did the COVID-19 pandemic affect post-transplant mortality rates?

The COVID-19 pandemic caused a significant increase in mortality rates among both diabetic and non-diabetic kidney transplant recipients. This increase was overwhelmingly driven by infection-related complications, particularly severe viral pneumonia. Chronic immunosuppressive therapy impaired neutralizing antibody responses after natural infection and vaccination, while diabetic individuals faced compounded risks due to underlying microvascular disease, baseline endothelial dysfunction, and preexisting cardiorespiratory comorbidities.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Oliveras L et al. Trends in mortality in adult first kidney transplant recipients with and without diabetes as cause of kidney failure: an ERA Registry study. Nephrol Dial Transplant. 2026 Aug 19. doi: undefined. PMID: 42616007.


2. Van Craenenbroeck AH, et al. New kidneys, old risks: cardiovascular challenges after transplantation. Nephrol Dial Transplant. 2026;41(6):998-1010.


3. Boerstra BA, et al. Kidney replacement therapy trajectories of patients with kidney failure: an ERA Registry study. Nephrol Dial Transplant. 2026;41(6):1105-1117.